Studying SIV to Understand HIV

Courtesy of Frank Kiernan  PICTURE OF HEALTH? This 15-year-old mangabey at the Yerkes National Primate Research Center in Atlanta has been SIV-infected for at least 10 years. In the past, physicians who treated AIDS patients understood that this deadly disease was one of immune deficiency. Their patients were immunosuppressed, subject to opportunistic infections, and had odd cancers. Today, because of continuing research on the human and primate immune systems and their responses to retr

Written byMyrna Watanabe
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

In the past, physicians who treated AIDS patients understood that this deadly disease was one of immune deficiency. Their patients were immunosuppressed, subject to opportunistic infections, and had odd cancers. Today, because of continuing research on the human and primate immune systems and their responses to retroviruses, AIDS researchers realize that the immunosuppression associated with AIDS is a result of chronic immune hyperactivation. Evidence for this comes from research on a primate called sooty mangabeys, which lives in equatorial Africa.

Sooty mangabeys normally contract simian immunodeficiency virus (SIV) through sexual contact. Despite evidence that SIV has direct toxic effects on CD4+ T cells, the monkey's immune system remains intact, as lost cells are replaced with new ones. This finding, published by Mark Feinberg and colleagues at Emory University School of Medicine,1 may be the clincher in a developing hypothesis: Virus-mediated, direct T-cell killing is not sufficient to cause AIDS; rather, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies